After that, much effort has been spent on the manufacture of second- and third-generation CAR T cells, and HER2 has been targeted with these CAR T cells in breast cancer, gastric cancer, sarcoma, glioblastoma, ovarian cancer, and also osteosarcoma [18]. This evidence concerns the gene ERBB2 and breast carcinoma.